Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AEGEAN: Neoadjuvant/Adjuvant Imfinzi in Resectable Stage II–III NSCLC
2023-509576-42-00Phase 3Authorised
- Sponsor
- AstraZeneca
- Start
- Aug 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Imfinzi arm with Placebo arm (2 arms). Primary endpoints: Event-free survival (EFS) in modified intent-to-treat (mITT) population and Pathological complete response (pCR) in modified intent-to-treat (mITT) population. Planned start Aug 2024; status: authorised.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2023-509576-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509576-42-00.